Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 4

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 8Sarcoma 6Genitourinary 6Gastrointestinal 6Tumor-Agnostic 4Other solid neoplasm 3Endocrine 3Breast 3Head & Neck 2Dermatologic 2CNS 2NET 1

Conditions

Neoplasms 4

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × cixutumumab × Tumor-Agnostic × Clear all
NCT01007032 2019-02-27

A Study of IMC-A12 in Advanced Solid Tumors

Eli Lilly and Company

Phase 1 Completed
21 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00785538 2019-01-08

A Study of IMC-A12 in Participants With Tumors Who No Longer Respond to Treatment or For Whom No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
24 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT00678769 2015-11-04

Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer

National Cancer Institute (NCI)

Phase 1 Completed
72 enrolled
Tumor-Agnostic

Neoplasms

NCT00785941 2011-10-13

A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available

Eli Lilly and Company

Phase 1 Completed
16 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡